In April 2015, the company signed a collaboration agreement with Professor Dan Grandér at the Department of Oncology and Pathology, Karolinska Institutet. Professor Grandér’s research group studies mechanisms for resistance development in tumors and together we have looked at how, and for which drugs, autophagy is a resistance mechanism. Since 2017, the collaboration has been deepened with a PhD student who shares their time between Sprint Bioscience and KI.
After a period of illness, Dan Grandér passed away in September 2017 and his research team is now led by associate professor Katja Pokrovskaja Tamm who has been a key person throughout the collaboration. Despite the loss of Dan, we continue to work together with the goal of turning autophagy inhibition into a clinically useful treatment.